Elucidating the genetic basis of imidazopyrazinone luciferin biosynthesis for the development of improved bioluminescence imaging technologies
阐明咪唑并吡嗪酮荧光素生物合成的遗传基础,以开发改进的生物发光成像技术
基本信息
- 批准号:9979650
- 负责人:
- 金额:$ 6.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-15 至 2021-08-14
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAmino AcidsAnabolismAnimal ModelAnimalsBiochemical MarkersBiologicalBioluminescenceBiomedical ResearchBiotechnologyCandidate Disease GeneCell Culture TechniquesCell membraneCodeCopepodaCuriositiesDevelopmentDiffuseDisease modelEnzymesEscherichia coliFermentationFluorescence MicroscopyGene Expression ProfilingGenesGeneticGrantGreen Fluorescent ProteinsHumanHuman Cell LineImageImaging technologyIn SituLeftLightLuciferasesMalignant NeoplasmsMicroscopyModelingNoiseOstracodsPathway interactionsPeptide YYProductionReagentReporterReporter GenesResearchResearch PersonnelSaccharomyces cerevisiaeSerumSignal TransductionTechnologyTestingTumor BurdenVariantYeastsZooplanktonbasebioluminescence imagingcoelenterazinecomparativecontrast imagingcostexperimental studyextracellularfluorescence imaginggene discoveryimprovedin vivoluciferinmetabolic engineeringmicroscopic imagingnovelsmall moleculetranscriptomics
项目摘要
Project Summary / Abstract
Coelenterazine and vargulin are naturally-occurring imidazopyrazinone luciferins used in
bioluminescence imaging, but their scarcity and need to supply them exogenously to cell culture
and animal models limit their use. I propose to elucidate the biosynthesis of these compounds in
bioluminescent zooplankton. In Specific Aim 1, I discuss the possible biosynthetic origins for
these molecules, and my plans to identify the genes coding for the requisite biosynthetic
enzymes. In Specific Aim 2, I describe how I would apply these newly-discovered genes to
economically produce coelenterazine by fermentation in S. cerevisiae, addressing a critical
barrier to progress. In Specific Aim 3, I propose initial experiments to assess whether the ability
to effect the luciferin’s biosynthesis in human cell culture model improves bioluminescence
imaging contrast. Successful completion of this project could have revolutionary impacts on
biological imaging, akin to how development of Green Fluorescent Protein from a biological
curiosity into a multipurpose biochemical marker has radically transformed the way we apply
microscopy and imaging to biological questions. Besides improving imaging signal-to-noise,
localized in situ luciferin production in cell culture could aid research into inter- and intracellular
signaling. Moreover, expression of the luciferin biosynthetic machinery in animals would allow
for long-term noninvasive in vivo bioluminescence experiments such as gene expression
monitoring and assessing tumor burden in cancer disease models.
项目总结/摘要
腔肠素和vargulin是天然存在的咪唑并吡嗪酮类维生素,用于
生物发光成像,但它们的稀缺性和需要将它们外源地提供给细胞培养
动物模型限制了它们的使用。我建议阐明这些化合物的生物合成,
生物发光浮游动物在具体目标1中,我讨论了
这些分子,以及我的计划,以确定必要的生物合成的基因编码,
内切酶在具体目标2中,我描述了如何将这些新发现的基因应用于
在S.酿酒厂,解决一个关键的
进步的障碍。在具体目标3中,我提出了初步实验,以评估是否有能力
在人类细胞培养模型中影响白蛋白的生物合成改善了生物发光
成像对比度该项目的成功完成可能会产生革命性的影响
生物成像,类似于如何从生物样品中开发绿色荧光蛋白,
好奇心变成了一种多用途的生化标记,
显微镜和成像来解决生物学问题。除了改善成像信噪比,
在细胞培养中的局部原位生产可以帮助研究细胞间和细胞内
发信号。此外,在动物中表达这种生物合成机制将允许
用于长期非侵入性体内生物发光实验,
监测和评估癌症疾病模型中的肿瘤负荷。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tristan de Rond其他文献
Tristan de Rond的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 6.53万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 6.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 6.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 6.53万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 6.53万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 6.53万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 6.53万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 6.53万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 6.53万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 6.53万 - 项目类别:
Standard Grant














{{item.name}}会员




